Finally, a Vaccine for Cancer
Episode
22 min
Read time
2 min
Topics
Health & Wellness, Software Development, Science & Discovery
AI-Generated Summary
Key Takeaways
- ✓Personalized mRNA vaccine mechanism: The melanoma vaccine sequences a surgically removed tumor's DNA, identifies up to 34 mutations that produce surface proteins the immune system can recognize as foreign, then delivers mRNA encoding those specific proteins. This trains each patient's immune system to detect and attack remaining cancer cells unique to their biology.
- ✓42% recurrence reduction with combination therapy: The vaccine works in conjunction with immune checkpoint inhibitors — drugs that block cancer cells from suppressing immune response. Patients received nine doses over roughly six months. This combination produced a 42% lower recurrence rate versus no vaccine, and reduced metastatic spread even when cancer did return.
- ✓Three enabling breakthroughs: Genome sequencing costs dropped from hundreds of millions of dollars to hundreds of dollars per individual. Immune checkpoint inhibitor drugs removed cancer's ability to suppress immune response. COVID-19 vaccine development taught Moderna to manufacture personalized mRNA at speed and scale — all three advances were required simultaneously.
- ✓Pancreatic cancer trial to watch: A 16-patient early-stage trial applying the same post-surgical mRNA vaccine approach to pancreatic cancer showed reduced recurrence. A larger randomized study is currently ongoing. Pancreatic cancer's notoriously poor prognosis makes this the most closely monitored next application of the melanoma vaccine framework.
- ✓Off-the-shelf prevention vaccines for high-risk patients: Researchers are developing non-personalized cancer vaccines targeting proteins common across specific cancer types, aimed at people with BRCA1/2 mutations, Lynch syndrome, or precancerous polyps. This approach could scale affordably compared to bespoke vaccines, which currently cost comparably to existing cancer therapies running into hundreds of thousands of dollars.
What It Covers
NYT health reporter Nina Agrawal explains how Merck and Moderna's personalized mRNA melanoma vaccine reduced cancer recurrence by 42% in a 1,100-patient trial over two years, marking the first clinically successful therapeutic cancer vaccine after more than a century of failed attempts across the field.
Key Questions Answered
- •Personalized mRNA vaccine mechanism: The melanoma vaccine sequences a surgically removed tumor's DNA, identifies up to 34 mutations that produce surface proteins the immune system can recognize as foreign, then delivers mRNA encoding those specific proteins. This trains each patient's immune system to detect and attack remaining cancer cells unique to their biology.
- •42% recurrence reduction with combination therapy: The vaccine works in conjunction with immune checkpoint inhibitors — drugs that block cancer cells from suppressing immune response. Patients received nine doses over roughly six months. This combination produced a 42% lower recurrence rate versus no vaccine, and reduced metastatic spread even when cancer did return.
- •Three enabling breakthroughs: Genome sequencing costs dropped from hundreds of millions of dollars to hundreds of dollars per individual. Immune checkpoint inhibitor drugs removed cancer's ability to suppress immune response. COVID-19 vaccine development taught Moderna to manufacture personalized mRNA at speed and scale — all three advances were required simultaneously.
- •Pancreatic cancer trial to watch: A 16-patient early-stage trial applying the same post-surgical mRNA vaccine approach to pancreatic cancer showed reduced recurrence. A larger randomized study is currently ongoing. Pancreatic cancer's notoriously poor prognosis makes this the most closely monitored next application of the melanoma vaccine framework.
- •Off-the-shelf prevention vaccines for high-risk patients: Researchers are developing non-personalized cancer vaccines targeting proteins common across specific cancer types, aimed at people with BRCA1/2 mutations, Lynch syndrome, or precancerous polyps. This approach could scale affordably compared to bespoke vaccines, which currently cost comparably to existing cancer therapies running into hundreds of thousands of dollars.
Notable Moment
In the 1890s, surgeon William Coley noticed a patient's tumor shrank spontaneously after a bacterial infection caused fever. He began injecting tumors with bacterial mixtures and observed regression in several patients — accidentally discovering immune stimulation as a cancer treatment, a principle dismissed for decades before modern science validated it.
Episode Transcript
Hi. I'm Andrew Ozorkin. I cover business and policy for DealBook, a daily newsletter at The New York Times. On November 18, I'm gonna be interviewing some of the most consequential leaders in business, politics, and culture, including JD Vance, Elon Musk, Christine Lagarde, Zoran Mamdani, and many others live on stage at the DealBook Summit in New York City. We're gonna be live streaming select interviews at nytimes.com and in the Times app on November 18. I hope you'll tune in. You won't wanna miss it. From New York Times, I'm Michael Bilbaro. This is The Daily. Today, a new experimental vaccine could become the first of its kind to treat cancer. My colleague, health reporter Nina Agrawal, explains how a century old idea is finally becoming a reality and where this breakthrough could lead to next. It's Monday, November 16. Nina, welcome back to The Daily. Hi, Michael. Thanks for having me. My pleasure. You come to us with some relatively big news from the world of cancer treatment, and everyone is fascinated and invested in us figuring out how to treat cancer. What are the developments? Yeah. I do have big news, and that is that really a first of its kind vaccine to treat cancer was shown to work. And explain why that's such a big deal. So scientists have tried and failed for decades, if not longer, to develop a vaccine that could be used to treat cancer. But it's really a very challenging thing. Why? You know, if you think about how vaccines work in infectious disease, we give somebody a vaccine to prevent the disease. And Flu, COVID. Correct. RSV. And cancer is... Even within a specific cancer, it's very varied. It's very heterogeneous. One person's cancer is not exactly the same as the next person's cancer. So you can't easily vaccinate all individuals against something that's gonna be so individualized. Right. Cancer by definition is the extremely unique mutation of a cell that becomes cancerous in your body. And it sounds like you're saying the impediment to a cancer vaccine is that you can't immunize the human body against the possibility so far that a cell is gonna go rogue. Right. I think here, the big breakthrough is actually being able to develop a vaccine that does respond to that individual nature of cancer. So what the scientists were able to do here was treat people who already have cancer with a vaccine that is individualized to that cancer. So very much changing the timeline of a vaccine from before someone gets sick to after they've already gotten cancer. Yeah. The way we traditionally think about vaccines against infectious disease being given when somebody is healthy and has no exposure. And this is a different paradigm where you're using it to treat cancer once somebody has already been diagnosed with it. Okay. So let's get into the specifics of exactly how this has worked. So, basically, what's happened now is that scientists …
Get the full transcript (3,696 words) + summary by email — free
One-time email with the complete transcript and AI summary of this episode. No account needed.
One email, no spam. We’ll also show you what SignalCast does.
You just read a 3-minute summary of a 19-minute episode.
Get The Daily (NYT) summarized like this every Monday — plus up to 2 more podcasts, free.
Pick Your Podcasts — FreeKeep Reading
More from The Daily (NYT)
The Ultraviolent, Wildly Successful, Uniquely American Phenomenon of Grand Theft Auto
Nov 15 · 42 min
a16z Podcast
Inside Moderna’s Personalized Cancer Vaccine
Sep 2
More from The Daily (NYT)
Olivia Wilde Hit Bottom. Here's How She Bounced Back.
Nov 14 · 50 min
The Genius Life
554: How to Use AI to Improve Your Health Right Now | Nasim Afsar, MD
Mar 2
More from The Daily (NYT)
We summarize every new episode. Want them in your inbox?
The Ultraviolent, Wildly Successful, Uniquely American Phenomenon of Grand Theft Auto
Olivia Wilde Hit Bottom. Here's How She Bounced Back.
Can Israel’s Opposition Unseat Netanyahu?
What Jensen Huang’s Potential Ouster Could Mean for A.I.
Public Schools Have a New Crisis: Not Enough Students
Similar Episodes
Related episodes from other podcasts
a16z Podcast
Sep 2
Inside Moderna’s Personalized Cancer Vaccine
The Genius Life
Mar 2
554: How to Use AI to Improve Your Health Right Now | Nasim Afsar, MD
Feel Better, Live More
Feb 18
How To Live Longer and Better: The Secret to Super Ageing with Dr Eric Topol #626
This Week in Startups
Feb 12
Why J-Cal Invested to 200K in a former Employee | E2249
The Doctor's Farmacy
Feb 4
How OpenAI Is Helping People Take Control of Their Health | Fidji Simo
Explore Related Topics
This podcast is featured in Best News Podcasts (2026) — ranked and reviewed with AI summaries.
Read this week's Health & Longevity Podcast Insights — cross-podcast analysis updated weekly.
You're clearly into The Daily (NYT).
Every Monday, we deliver AI summaries of the latest episodes from The Daily (NYT) and 192+ other podcasts. Free for one show.
Start My Monday DigestNo credit card · Unsubscribe anytime